XASE · Healthcare · Biotechnology
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Phage therapy biotech posts devastating **$7.02 EPS miss** at $-7.38. Clinical-stage company targeting diabetic foot infections struggles with cash burn acceleration.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | -0.36 | -7.38 | -1950.00% | $0 | ❌ Miss | +5.93% | +159.68% | — |
| 2025-11-12 | Q3 2025 | -0.32 | -0.29 | +9.38% | $0 | ✅ Beat | — | — | — |
| 2025-08-13 |
| Q2 2025 |
| -0.29 |
| -0.19 |
| +34.48% |
| $0 |
| ✅ Beat |
| -0.05% |
| +4.78% |
| -4.35% |
| 2025-03-25 | Q4 2024 | — | -0.91 | — | $0 | — | -11.05% | -15.70% | +4.41% |
| 2024-11-14 | Q3 2024 | — | -0.31 | — | $0 | — | -17.33% | -34.43% | -11.33% |
| 2024-08-14 | Q2 2024 | — | -0.70 | — | $0 | — | -11.58% | -17.93% | -46.05% |
| 2024-05-20 | Q1 2024 | — | -2.80 | — | $0 | — | +6.85% | +5.42% | -3.02% |
| 2024-04-03 | Q4 2023 | — | -0.80 | — | $0 | — | +8.57% | -2.43% | +9.69% |
Showing last 8 quarters.